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Challenges in idiopathic pulmonary fibrosis
trials: the point on end-points
C. Albera
ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias and is associated with both a variable clinical course and a poor prognosis.
Investigators involved in clinical trials and clinicians reviewing the IPF literature are confronted
with daunting challenges in selecting reliable outcome measures, interpreting the clinical and
statistical importance of these findings, and applying this knowledge to the clinical care of their
patients. In order to evaluate the efficacy of new treatment regimens, a number of studies have
been performed, employing a range of clinical and surrogate end-points. In most studies, the
primary end-point consists of a single outcome measure. A desirable single clinical end-point for
IPF should be reliable, valid, responsive to changes in disease status, clinically meaningful,
predictive of clinical outcome and responsive to treatment effect of a given intervention. Proper
consideration and effective choice of outcome measures used in IPF studies will help establish
effective and achievable drug development programmes and will enable clinicians and
investigators to make informed critical decisions in recommending a treatment regimen to their
IPF patients.
KEYWORDS: End-points, forced vital capacity, idiopathic pulmonary fibrosis, idiopathic
pulmonary fibrosis trials, 6-min walk test
I
diopathic pulmonary fibrosis (IPF) is a pro-
gressive, life-threatening interstitial lung dis-
ease (ILD). It has a significant impact on the
quality of life of patients, and the prognosis is
worse than most other ILDs [1–3].
In IPF, lung parenchyma architecture is irrever-
sibly disrupted with resulting functional impair-
ment [2]. No cases of spontaneous regression
have been observed; presumably because there
is no way the fibrotic change can be reversed.
However, within this framework, there is a high
degree of inter-individual variability with respect
to disease extent, disease progression and survi-
val time [2, 4]. One study has shown that the
clinical course of patients with mild-to-moderate
IPF is characterised by: 1) minimal physiological
deterioration as measured by forced vital capa-
city (FVC), diffusing capacity of the lung for
carbon monoxide (DL,CO) and alveolar–arterial
oxygen tension difference (PA-a,O2); 2) frequent
hospitalisations for respiratory disorders; and
3) an acute, rapid and fatal deterioration of
lung disease in almost half of the patients who
die from an IPF-related cause [5]. The marked
variability in the extent and rate of disease
progression from one individual to the next
means that early and accurate diagnosis and
early referral may give the best chance of optimal
therapy, as response rates may be higher when
treatment is initiated before the development of
irreversible fibrosis [1, 2]. As the diagnosis of
definite IPF is frequently made without surgical
lung biopsy, it is relevant to ask whether the
method of diagnosis could influence treatment
outcomes, i.e. whether it could act as bias for any
end-point. It has been demonstrated in a well-
defined cohort of IPF patients that neither disease
severity, as assessed by baseline FVC % pre-
dicted, nor rate of disease progression, as
assessed by change in FVC % predicted, were
significantly different in patients who had a
surgical lung biopsy compared with those who
did not. Moreover, the treatment effect for
pirfenidone was similar in patients with and
without a surgical lung biopsy [6].
PRIMARY END-POINTS
Reliable, objective parameters to assess disease
progression and treatment response are currently
poorly defined and not fully validated. Thresholds
for change in several lung function parameters
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(total lung capacity, FVC, single-breath DL,CO, arterial oxygen
pressure, PA-a,O2 and oxygen saturation) have been identified as
representative of a favourable or improved response to therapy
in patients with IPF [2]. However, there are insufficient data
to establish whether these are the most reliable and valid
measurements of therapeutic efficacy [7]. Attempts to identify
clinical and surrogate end-points for IPF clinical trials have
either failed or merely provided positive signals, generating
hypotheses requiring further investigation [7–10]. In the past
20 yrs many clinical trials have been conducted to evaluate the
efficacy and safety of different and innovative drugs in the
treatment of IPF. Table 1 demonstrates the heterogeneity of
primary end-points used in these trials [8, 9, 11–18]. Studies
have generally measured lung function as this is the most valid
end-point. However, the challenges involved in choosing the
most appropriate outcome have not been discussed in these
papers.
Regulatory guidance from the US Food and Drug Ad-
ministration (FDA) has identified several key parameters with
regard to end-points [19]. The FDA assessment acknow-
ledges that interpreting change in lung function in IPF is
challenging, but proposes that a categorical reduction in FVC
of o10% could be regarded as clinically meaningful based on
available evidence. Mortality is identified as the ideal and most
compelling primary end-point in clinical trials, particularly
as there are no well-established or validated surrogates for
mortality in IPF. However, the importance of other clinically
meaningful end-points is highlighted, including: survival;
survival plus disease progression (composite end-point); pre-
servation of lung function; dyspnoea; functional status; and
quality of life. It is important to note that mortality findings
should be supportive of other clinical end-points [19].
IPF CLINICAL END-POINTS: DESIRABLE
CHARACTERISTICS
A desirable single clinical end-point for IPF should be reliable,
valid, responsive to changes in disease status, clinically
meaningful, predictive of clinical outcome and responsive to
treatment effect of a given intervention.
Reliability
A reliable clinical end-point is one that offers stability of
measurement. The distance walked at the 6-min walk test
(6MWT) is a practical, simple assessment of self-paced exercise
capacity [20]. The test is very reliable in patients with IPF,
showing only small variation when repeated in the same
subject over a short period of time (coefficient of variation
4.2%) [21]. The 6MWT is well established as a surrogate end-
point in clinical studies of pulmonary arterial hypertension
(PAH) [22]. Recently, the reliability of the 6MWT in IPF was
assessed using data from the largest clinical trial to date
(INSPIRE (effect of interferon c-1b on survival in patients with
idiopathic pulmonary fibrosis); n5822). Comparison of the
6MWT on two separate days (mean interval 24 days) demon-
strated high reliability (intraclass correlation coefficient 0.82;
p,0.001) [23].
Validity and responsiveness to changes in disease status
A good end-point should correlate well with other measures of
disease status (validity) and should be responsive to changes
in disease status. FVC is widely used and accepted as a
clinically meaningful measure of IPF disease status [2]. Recent
data show that when FVC and 6MWT are assessed for validity
and responsiveness using other functional parameters (DL,CO,
the St George’s Respiratory Questionnaire score and the
University of California, San Diego, Shortness of Breath
Questionnaire score), the correlations are statistically signifi-
cant (p,0.001), if rather weak (figs 1 and 2) [23, 24].
Ability to show clinically meaningful difference
One of the key challenges that the investigator faces when
selecting primary outcome measures, is determining the
significance of any observed differences (statistical significance
versus clinical relevance) and communicating the same to
clinicians who will be applying the trial results. Minimal
clinically important difference (MCID) is defined as the
smallest difference in an outcome measure that patients would
perceive to be important and that would lead a clinician to
consider a change in a patient’s status [25]. Estimated MCID
for FVC is approximately three to five units and for 6MWT is
23–45 m [23, 24].
Ability to predict clinical outcome
A valid end-point should correlate reasonably well to clinical
outcome (survival). A number of end-points have been found
to be predictors of mortality in published IPF studies,
including: FVC [7, 26–29]; DL,CO (% pred) [7, 26, 29];
alveolar–arterial gradient [7, 27]; dyspnoea [27]; 6MWT
desaturation (,88%) [30]; 6MWT distance [23, 31, 32], high-
resolution computed tomography (HRCT) fibrosis score [33];
HRCT pattern (typical/atypical) [34]; and respiratory hospita-
lisation [1]. Of these, FVC and 6MWT can be considered as the
best predictors of mortality at baseline in IPF. Published
literature has identified a categorical reduction of o10% in
FVC as both reliable and predictive of mortality, and is
associated with a greater than two-fold increase in the risk of
death [7, 27, 28]. It has also been noted that a change in 6MWT
(walked distance in m) is highly predictive of mortality;
TABLE 1 Primary end-points of idiopathic pulmonary
fibrosis clinical trials performed in the last 20 yrs
NOBLE et al. [11] FVC
TANIGUCHI et al. [12] VC
DANIELS et al. [13] PFS#
KING et al. [14] Survival
RAGHU et al. [15] FVC DL,CO Pa,O2
KING et al. [16] 6MWT
KUBO et al. [17] Survival
DEMEDTS et al. [18] VC DL,CO
AZUMA et al. [8] Pa,O2
" 6MWT"
RAGHU et al. [9] PFS+
FVC: forced vital capacity; VC: vital capacity; DL,CO: diffusing capacity of the
lung for carbon monoxide; Pa,O2: arterial oxygen tension; 6MWT: 6-min walk
test; PFS: progression-free survival. #: time to disease progression defined as
decline in FVC (%) from baseline predicted FVC or death; ": lowest arterial
oxygen saturation measured by pulse oximetry during 6MWT; +: defined as
o10% decline from baseline of predicted VC or an increase o5 mmHg in the
alveolar–arterial oxygen tension difference at rest.
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a 24-week decrement of .50 m was associated with a four-fold
increase in the risk of death over the subsequent 12 months
(p,0.001) [23].
The validation of a simple, reproducible measure of outcome
in a mortality scoring system is an important but challenging
task. A mortality risk scoring model for patients with 1PF
was recently provided by DU BOIS et al. [35]. The proposed
abbreviated clinical model comprises four readily available
clinical measures of disease status (age, FVC at baseline,
24-week change in FVC and 24-week history of respiratory
hospitalisation) that reliably predict 1-yr mortality in patients
with IPF. This simplified scoring system may be a valuable tool
for determining mortality risk of IPF patients in clinical practice,
facilitating clinical decision making in the management of
patients with IPF [35].
Sensitivity to treatment effect
VALEYRE et al. [36] have assessed the longitudinal change in
FVC and 6MWT in pooled pirfenidone 2,403 mg?day-1 (n5345)
and placebo (n5347) groups from the CAPACITY trials. FVC
and 6MWT distance were measured at baseline and at 12-week
intervals until week 72. The pattern of change over time in FVC
and 6MWT in the two groups was found to be very similar
(fig. 3). The treatment effect for both outcome measures was
evident at week 12, reached a peak at week 36 and persisted
through week 72. However, the correlation at week 72 across
these two measurements in individual patients was weak
(r250.10 for both groups), suggesting that these outcomes
measure different functional domains of the IPF disease
process [36].
COMPOSITE END-POINTS
Composite end-points take two or more outcome measures
and combine them into a single outcome measure [37].
Composite end-points have been used to increase the overall
event rate and thereby reduce the number of patients needed
for a clinical trial. A well-designed and validated composite
end-point can provide a reliable means of testing new
treatments using a trial of relatively short duration [38]. A
composite end-point may also address the issue of multiplicity
(no adjustment to type 1 error required), may help to assess the
‘‘net effect’’ of treatment, and can be a useful support for the
choice of a primary end-point [37, 38]. A composite end-point
should meet the following criteria: each component is clinically
meaningful and biologically plausible; each component is
sensitive to treatment; the expected treatment effect on each
component is similar; and each component can be analysed and
reported individually [39]. A composite end-point that includes
measures of outcome clearly related to the mortality risk seems
to be one of the more reliable end-points for IPF clinical studies.
Thus, progression-free survival, the end-point usually employed
for lung cancer (a disease whose biology is in some respects
similar to that of IPF) [40–42], could potentially be suggested as
an optimal composite end-point for IPF.
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FIGURE 1. Validity correlations between 6-min walk distance (6MWD) and other functional
parameters. FVC: forced vital capacity; UCSD SOBQ: University of California, San Diego, Shortness of
Breath Questionnaire; DL,CO: diffusing capacity of the lung for carbon monoxide; SGRQ: St George’s
Respiratory Questionnaire. Data taken from [24].
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CONCLUSION
The clinical course of IPF is variable and its natural history poses
many challenges for clinical research. Investigators involved in
the planning of IPF clinical studies face considerable challenges
in selecting outcome measures that will allow statistical
assessment of clinically meaningful effects or outcomes. A
number of clinical and surrogate end-points have been
proposed and evaluated in studies. Changes in FVC and
6MWT have been found to be reliable, valid and responsive
clinical outcome measures in patients with IPF. Mortality, the
ideal and most compelling primary end-point, can be useful but
is challenging to study requiring large cohorts of patients and
long-lasting studies. Since there is increasing evidence indi-
cating that the fundamental hallmarks of cancer biology
are comparable to those of IPF, the primary end-point of
progression-free survival, which is usually employed for lung
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FIGURE 3. The pattern of change over time (72 weeks) in a) forced vital capacity (FVC) and b) 6-min walk test (6MWT) in patients receiving pirfenidone (h: n5345) or
placebo (&: n5347). #: p50.005; ": p50.001. Adapted from [36].
FIGURE 2. Responsiveness correlations between changes in 6-min walk distance (6MWD) and
other functional parameters. FVC: forced vital capacity; UCSD SOBQ: University of California, San
Diego, Shortness of Breath Questionnaire; DL,CO: diffusing capacity of the lung for carbon monoxide;
SGRQ: St George’s Respiratory Questionnaire. Data taken from [24].
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cancer, could be potentially suggested as an end-point for IPF.
The predictive value of easily measured and reliable clinical and
physiological variables could improve the care of patients with
IPF. However, more studies are needed to improve treatment of
IPF with current and new compounds, alone or in combination.
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